Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
FDA green and red lights: May 2024
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
